Clopidogrel or apixaban in atrial fibrillation patients unsuitable for vitamin-K antagonists for stroke prevention in atrial fibrillation? Lessons from the recent aspirin-controlled trials

被引：0
|
作者：
Verheugt, F. W. A. [1 ]
Jaspersfocks, J. [2 ]
Brouwer, M. A. [2 ]
机构：
[1] Onze Lieve Vrouw Hosp, Amsterdam, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Cardiol, NL-6525 ED Nijmegen, Netherlands
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2011年 / 183卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：672 / 672
页数：1
相关论文
共 50 条
  • [31] Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation
    Seiffge, David J.
    Paciaroni, Maurizio
    Wilson, Duncan
    Koga, Masatoshi
    Macha, Kosmas
    Cappellari, Manuel
    Schaedelin, Sabine
    Shakeshaft, Clare
    Takagi, Masahito
    Tsivgoulis, Georgios
    Bonetti, Bruno
    Kallmuenzer, Bernd
    Arihiro, Shoji
    Alberti, Andrea
    Polymeris, Alexandros A.
    Ambler, Gareth
    Yoshimura, Sohei
    Venti, Michele
    Bonati, Leo H.
    Muir, Keith W.
    Yamagami, Hiroshi
    Thilemann, Sebastian
    Altavilla, Riccardo
    Peters, Nils
    Inoue, Manabu
    Bobinger, Tobias
    Agnelli, Giancarlo
    Brown, Martin M.
    Sato, Shoichiro
    Acciarresi, Monica
    Jager, Hans Rolf
    Bovi, Paolo
    Schwab, Stefan
    Lyrer, Philippe
    Caso, Valeria
    Toyoda, Kazunori
    Werring, David J.
    Engelter, Stefan T.
    De Marchis, Gian Marco
    ANNALS OF NEUROLOGY, 2019, 85 (06) : 823 - 834
  • [32] New oral anticoagulants are inferior to vitamin-K-antagonists for stroke prevention in elderly patients with atrial fibrillation
    Guenduez, D.
    Finsterer, J.
    WIENER KLINISCHE WOCHENSCHRIFT, 2013, 125 : S28 - S28
  • [33] Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis
    Van Der Meersch, Hans
    De Bacquer, Dirk
    De Vriese, An S.
    AMERICAN HEART JOURNAL, 2017, 184 : 37 - 46
  • [34] Safety and Effectiveness Outcomes between Apixaban Versus Vitamin K Antagonists in Atrial Fibrillation Patients on Dialysis
    Guo, Zongwen
    Wang, Yufan
    Ding, Xiaoli
    Lai, Jiying
    Chen, Yijian
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2024, 25 (09)
  • [35] Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin - Stroke prevention in atrial fibrillation III study
    Anderson, DC
    Halperin, JL
    Hart, RG
    McAnulty, JH
    McBride, R
    Pearce, LA
    Sherman, DG
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (16): : 1273 - 1277
  • [36] Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists
    Emilie Gieling
    Frank de Vries
    Rachael Williams
    Hein A. W. van Onzenoort
    Anthonius de Boer
    Vincent ten Cate
    Cornelis Kramers
    Andrea Burden
    International Journal of Clinical Pharmacy, 2019, 41 : 1536 - 1544
  • [37] Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists
    Gieling, Emilie
    de Vries, Frank
    Williams, Rachael
    van Onzenoort, Hein A. W.
    de Boer, Anthonius
    ten Cate, Vincent
    Kramers, Cornelis
    Burden, Andrea
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (06) : 1536 - 1544
  • [38] Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation
    Seeger, Julia
    Woehrle, Jochen
    CORE EVIDENCE, 2020, 15 : 1 - 6
  • [39] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Thitima Kongnakorn
    Tereza Lanitis
    Lievens Annemans
    Vincent Thijs
    Sophie Marbaix
    Clinical Drug Investigation, 2014, 34 : 709 - 721
  • [40] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Kongnakorn, Thitima
    Lanitis, Tereza
    Annemans, Lievens
    Thijs, Vincent
    Marbaix, Sophie
    CLINICAL DRUG INVESTIGATION, 2014, 34 (10) : 709 - 721
12345